Citations

Clear

513 citation(s) found for "Ta, Casey".

Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial
Gadi, Sanjay, Maselli, Daniel B. , Donnangelo, Lauren L., Wooley, Chase, Comer, Taylor, Casey, Shannon, Jain, Ankit , Jain, Aditya, Chapman, Christopher G., Bakheet, Nader , Badurdeen, Dilhana, Kumbhari, Vivek , McGowan, Christopher , Gadi, Sanjay R V , Wooley, Chase

Mayo Clinic

Endoscopy | February 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2823-8603 | PMID 41760139 Get It

Abstract Endoscopic sleeve gastroplasty (ESG) facilitates 13.6%–16.2% total body weight loss (TBWL) at 12 months, but falls short of that seen with surgical vertical sleeve gastrectomy, in part owing to the retention of the gastric fundus. In adults with obesity, gastric fundal mucosal ablation (GFMA) reduces fasting plasma ghrelin (FPG), hunger, cravings, and accommodation. Combined GFMA-ESG could improve TBWL. This study aimed to evaluate the effectiveness and safety of sequential GFMA followed by ESG in adults with obesity, building on previously published 6-month results of GFMA alone. This was a prospective, first-in-human, two-phase clinical trial. Ten participants underwent GFMA, followed by ESG at month 6, and were followed for 12 months post-ESG (18 months total). GFMA was performed using hybrid argon plasma coagulation to lift and ablate the entire gastric fundal mucosa. ESG was performed using standard full-thickness endoscopic suturing of the gastric body. The primary end point was TBWL; secondary end points were safety and changes in FPG, maximum tolerated volume (MTV), and validated appetite questionnaires. Mean TBWL was 22.5% (SD 8.3%) at month 18. Hunger-related behaviors and eating self-efficacy showed sustained improvements. FPG was decreased at month 6 and returned toward baseline by month 18, while MTV remained suppressed. No serious adverse events occurred. Sequential GFMA-ESG is safe and induces substantial weight loss, reduced MTV of ingested nutrients, and improved behavioral measures. This combination approach builds on prior traditional ESG and GFMA-only results and may represent a promising advancement of endoscopic therapeutic options for weight loss.
Breast Implants and Pectus Deformity Repair: A Retrospective Study and Clinical Recommendations
Khedr, Ahmed E. , Zeineddine, Rawan M. , Odeh, Nour B., Senjab, Abdulrahman , Farina, Juan M, Rebecca, Alanna M. , Casey, W. B., Rhee, Dan H, Reece, Edward M., Jaroszewski, Dawn E. , Farina, Juan M.

Mayo Clinic

Journal of the American College of Surgeons | February 24, 2026 | Volume: 243 | Issue: 1 | Pages: 130-140

10.1097/xcs.0000000000001882 | PMID 41733249 Get It

BACKGROUND: Pectus deformities are common chest wall abnormalities, with surgical correction recommended for severe cases. Female patients undergoing repair may have a history of breast implants or seek concurrent augmentation. This retrospective study examines clinical implications of pectus repair in patients with breast implants and provides recommendations. STUDY DESIGN: A retrospective review of female patients undergoing pectus repair at Mayo Clinic Arizona (January 1, 2010 to February 1, 2025) was conducted. Outcomes and complications were analyzed in patients with and without breast implants. RESULTS: In total, 456 female patients were included (447 excavatum, 7 arcuatum, and 2 carinatum; median age 32.7). Most patients (78.5%) underwent primary minimally invasive repairs (MIRPE); 6.6% underwent primary hybrid MIRPE, 5.5% underwent redo MIRPE, and 9.4% underwent primary redo open and complex reconstructions. In total, 104 patients (22.8%) had a history of breast implants, with 68 patients having breast implant-related procedures at the time of pectus surgery. At 12 months, the cumulative incidence of infection was significantly higher in patients with implants present at the time of pectus repair than in those without (8.8% vs 1.8%; log rank, p = 0.0015). A 4.9-fold increase in overall infection was seen in patients with indwelling or placed implants during pectus surgery. Deep infections were significantly more common in patients with implants (4.4%) than without (1.0%; p = 0.035). Similarly, superficial infections were more frequent in patients with implants (4.4%) than without (0.8%; p = 0.016). At 30 days, patients with implants had higher rates of infection (p = 0.032), pneumothorax (p = 0.008), and hematoma (p = 0.027), with no significant differences in other complications. CONCLUSIONS: Breast implants at the time of pectus repair were associated with increased risk of postoperative infection, pneumothorax, and hematoma. Removal of implants before pectus repair is recommended with delayed replacement, if desired.
Abstract C010: Anti-FN14 CAR-T cells overcome TGF-β-mediated suppression, and their synergy with methylseleninic acid enhances cytotoxicity and effector function in kidney, prostate, and brain tumors
Ager, Casey R. , Rustum, Youcef M. , Kim, Gloria B. , Amissah, Obed Boadi , Zakharia, Yousef

Mayo Clinic

Cancer Immunology Research | February 18, 2026 | Volume: 14 | Issue: 2_Supplement | Pages: C010-C010

10.1158/2326-6074.io2026-c010 Get It

Abstract Background: Clear cell renal cell carcinoma (ccRCC), metastatic castration-resistant prostate cancer (mCRPC), and glioblastoma (GBM) are highly treatment-refractory tumors characterized by elevated TGF-β1, a key suppressor of antitumor immunity and antigen presentation. Because CAR-T cells infiltrating these tumors experience persistent physiologic TGF-β exposure, assessing CAR-T functional resilience across increasing TGF-β concentrations is critical for determining therapeutic feasibility. Methylseleninic acid (MSA), a pharmacologic selenium compound, potently inhibits TGF-β1, PD-L1, and VEGF with minimal off-target toxicity. FN14, the TWEAK receptor and a metastasis driver, is selectively overexpressed in these malignancies, making it a high-specificity CAR target. Methods: We developed second-generation anti-FN14 CARs containing CD28 or 4-1BB costimulatory domains and a CD3ζ signaling motif, then lentivirally transduced into primary human CD4+ and CD8+ T cells. Cytotoxicity against FN14+ ccRCC, mCRPC, GBM lines and patient-derived cells was assessed using LDH release and xCELLigence assays. Effector function was evaluated through intracellular cytokine profiling, multiplex analysis, and phenotypic characterization by flow cytometry. CAR-T persistence in TGF-β-rich conditions was measured using CCK-8 proliferation assays, and Ki-67 and activation/exhaustion markers (PD-1, CXCR3) in the presence of 0-10 ng/mL TGF-β. MSA’s immunomodulatory and synergistic effects were tested at physiologically concentrations to measure impacts on CAR-T viability, metabolic activity, cytokine secretion, and tumor cell susceptibility. Results: Anti-FN14 CAR-T cells mediated rapid, antigen-specific lysis across all tumor types, achieving >50% specific killing at a 1:1 E:T ratio. MSA (2.5-5 µM) reduced tumor PD-L1 and TGF-β expression by >40% and enhanced CAR-T metabolic activity, IL-2, and IFN-γ secretion. CAR-T cells maintained comparable proliferation and activation in 0-5 ng/mL TGF-β, indicating that antigen-driven signaling counteracted low-to-moderate TGF-β-mediated suppression. Ex vivo CAR-T manufacturing with MSA (2.5 µM) improved cytotoxicity and persistence versus untreated CAR-T cells (p < 0.01). MSA’s effects were dose- and schedule-dependent and remained within human-relevant exposure ranges without detectable toxicity. Conclusion: MSA enhances anti-FN14 CAR-T cytotoxicity, metabolic fitness, and sustained effector activity by suppressing tumor-derived TGF-β1 and PD-L1 and by directly improving CAR-T functional capacity. Consistent with this mechanism, physiological TGF-β levels (0-5 ng/mL) did not significantly impair CAR-T proliferation or activation, demonstrating intrinsic resilience of FN14 CAR-T cells in TGF-β-rich environments. As a clinically relevant TGF-β1 inhibitor and active metabolite of seleno-L-methionine, MSA represents a readily translatable strategy to reduce CAR-T exhaustion and enhance efficacy in TGF-β-rich solid tumors including ccRCC, mCRPC, and GBM. Citation Format: Obed B. Amissah, Casey Ager, Yousef Zakharia, Youcef M. Rustum, Gloria B. Kim. Anti-FN14 CAR-T cells overcome TGF-β-mediated suppression, and their synergy with methylseleninic acid enhances cytotoxicity and effector function in kidney, prostate, and brain tumors [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C010.
Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer
Gupta, G., Ho, A. Y., Gharibpoor, Faeze , Abdou, Y., Anampa, J. D., Blitzblau, R. C., Calhoun, B. C., Dent, S. F., Carey, L. A., Bellon, J. R., Warren, L. E., Lu, J., Hieken, T. J., Taghian, A. G., Bardia, A., Traina, T. A., Plitas, George , Gallagher, K., Daugherty, K., Thompson, A. M., Krop, I., Wolff, A., Mittendorf, E. A., Fox, J., Hwang, E., Khan, A. J., Loene, J. P., Mutter, R., Patil, S., Santa-Maria, C., Vincent, B. V., Wright, J. L., Spring, L., Gupta, Gaorav P , Blitzblau, R.C., Calhoun, B.C., Casey, Dana L. , Dent, Susan , Bellon, J.R., Warren, LE, Hieken, Tina J. , Bardia, Aditya , Gallagher, K.K., Thompson, A. M., Krop, Ian E. , Mittendorf, E. A., Garber, Haven R. , Mutter, Robert W. , Santa-Maria, C.A.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS2-05-GS2-05

10.1158/1557-3265.sabcs25-gs2-05 Get It

Abstract Introduction: Hormone receptor positive (HR+), HER2- breast cancer (BC) is the most common subtype of BC. Despite advances in chemotherapy and endocrine therapy optimization, local and systemic recurrences frequently occur, especially for patients with node-positive disease. Recent data suggest a subset of patients with this tumor phenotype may benefit from the addition of anti-Programmed Death-1(aPD1) to neoadjuvant chemotherapy. However, T-cell infiltration (TCI), a biomarker of response to aPD1 and chemotherapy, is typically low in this BC subtype. Preclinical models show that combining preoperative radiation therapy (preop RT) with immune checkpoint inhibitors can enhance TCI and anti-tumor immunity. We conducted the first randomized trial to test whether no-, low- or high-dose RT combined with aPD1 increases TCI and improves responses in non-irradiated, metastatic lymph nodes in HR+/HER2- BC (NCT04443348). Materials & Methods: Eligible patients had ER and/or PR≥10%, HER2 negative invasive BC with clipped and biopsy-proven positive axillary node(s), cT1c-T4c, cN1-3, and at least one of the following criteria: grade 3 or grade 1-2 with cN2-N3, Ki67 >20%, or high genomic assay score. Between 2022-2024, 51 patients from 10 centers were randomized to no (0Gy; control arm), low (9Gy) or high (24Gy) doses of preop RT to the primary tumor with concurrent pembrolizumab followed by a 2-week tumor biopsy. Stratification factors were T1c vs. T2-4 and N1 vs. N2-3. Patients subsequently received pembrolizumab with 12 weeks of paclitaxel, followed by 4 cycles of adriamycin-cyclophosphamide (q2wk or q3wk) with pembrolizumab (200 mg q3 wks or 400 mg q6 wks). Surgery and adjuvant therapy followed standard-of-care. Dual co-primary endpoints were 2wk tumor TCI and nodal pathologic complete response (ypN0) at time of definitive surgery. TCI was assessed by multiplex immunofluorescence (pan-cytokeratin, CD3, CD8), using a rank-based Immunoscore (range 0-1), compared to baseline reference biopsies via two-tailed Mann-Whitney test. ypN0 was evaluated non-comparatively. Secondary endpoints included pCR and Residual Cancer Burden (RCB) 0/1. Results: Among 51 patients enrolled, 49 were evaluable for TCI and 48 for the ypN0 endpoint. Median age was 49.5 years (range 23-78). The cohort had a high-risk clinical profile: 92% had cT2-4, 50% N2-3, and 62% grade 3 tumors. Median ER and PR positivity were 90% (20-100) and 68% (1-98), respectively. Multifocal or multicentric tumors were present in 32%. TCI was assessed at 2 weeks post-treatment. The proportion of tumors with TCI in the upper quartile increased with RT dose escalation: 31% (0Gy), 40% (9Gy), and 53% (24Gy). Median TCI scores at 2 weeks were 0.60 (0Gy), 0.56 (9Gy), and 0.82 (24Gy), compared to a median baseline value of 0.50 from untreated reference samples. A statistically significant increase in TCI was observed only in the 24Gy cohort relative to the untreated group (p=0.027). 70.8% underwent mastectomy, with 39.6% receiving immediate reconstruction. 8% experienced G2/3 wound complications, balanced across arms. Median number of lymph nodes removed was 6.5 (1-42). The overall ypN0 rate was 29%, and 24%(0Gy), 29%(9Gy) and 33%(24Gy) per arm. pCR/RCB 0-1 rates were 18%/27% in the entire cohort and 6%/18%(0Gy), 29%/29%(9Gy), and 19%/33%(24Gy), respectively. Conclusion: The addition of 24Gy preop RT to aPD1 significantly increased tumor TCI in HR+/HER2- early-stage BC. Non-irradiated nodal response rates were promising despite over one-third of the study population with grade 1/2 tumors and high disease burden, laying the foundation for a future randomized trial comparing the efficacy of this novel approach against standard of care for node-positive HR+/HER2- BC. Citation Format: G. Gupta, A. Y. Ho, F. Gharibpoor, Y. Abdou, J. D. Anampa, R. C. Blitzblau, B. C. Calhoun, D. L. Casey, S. F. Dent, L. A. Carey, J. R. Bellon, L. E. Warren, J. Lu, T. J. Hieken, A. G. Taghian, A. Bardia, T. Traina, G. Plitas, K. Gallagher, K. Daugherty, A. Thompson, I. Krop, A. Wolff, E. Mittendorf, J. Fox, H. Garber, E. Hwang, A. J. Khan, J. P. Loene, R. Mutter, S. Patil, C. Santa-Maria, B. V. Vincent, J. L. Wright, L. Spring.Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS2-05.
Prior Out-of-Home Placement and Length of Stay Among Youths Receiving Mental Health Services in the ED
Kelly, Casey K., Saliba, Maria , Park, Jin Hong , Yoshii, Helder K., Tarikogullari, Idil , Tarasewicz, Abby T., Kaase, Alexandra L., Porter, C B, Boehm, Stacey M., Loy, Sydney N., Romanowicz, Magdalena , Taylor-Desir, Monica, Tarasewicz, Abby, Kaase, Alexandra, Porter, Caleb, Taylor-Desir, Monica J., LeMahieu, Allison , Taylor-Desir, Monica

Mayo Clinic

JAMA Network Open | January 23, 2026 | Volume: 9 | Issue: 1 | Pages: e2555339

10.1001/jamanetworkopen.2025.55339 | PMID 41575744 Get It

Importance Youth mental health crises have been increasing over the last decade, and there is an urgent need for clinicians to be more knowledgeable about patients with high emergency department (ED) utilization. Several disparities in ED utilization and outcomes have already been identified; however, little data exist on disparities affecting youths with histories of out-of-home placement (OOHP). Objective To explore whether history of OOHP is associated with increased length of stay among child and adolescent patients who present to the emergency department with psychiatric symptoms. Design, Setting, and Participants This retrospective, electronic health record (EHR)–based, cross-sectional study included patients aged 17 years or younger with a child and adolescent psychiatric consultation placed in the Mayo Clinic Rochester ED between January 1, 2021, and June 30, 2024. The Mayo Clinic Rochester is a tertiary referral center that serves as a regional hub for both primary and specialized psychiatric care. Main Outcomes and Measures The primary outcome was the length of stay in the ED. Secondary outcomes were use of physical and pharmacological restraint. Associations between OOHP and length of stay were examined via linear mixed-effects regression models with length of stay log transformed. Results Of the 1572 care encounters (median [IQR] age, 14,9 [13.3-16.3] years) among 1119 unique patients, there were 1244 with no history of OOHP and 328 with history of OOHP. Among the OOHP group, 158 (48%) were male and 170 (52%) female; 11 (4%) American Indian or Alaska Native, 7 (2%) Asian, 49 (16%) Black, 43 (14%) Hispanic, and 222 (71%) White. Among the 1244 encounters without OOHP, 820 (66%) were among female patients and 423 (34%) male; 21 (2%) American Indian or Alaska Native, 47 (4%) Asian, 121 (10%) Black, 125 (10%) Hispanic, and 971 (80%) White. Children and adolescents with history of OOHP were observed to spend 24% (95% CI, 12%-36%) more time in the ED even when adjusting for age at admission, sex, insurance, number of prior diagnoses, presenting concerns, and reasons for prolonged boarding ( P = .004). Children and adolescents with history of OOHP had 2.05 (95% CI, 1.69-2.48) higher odds of being physically restrained ( P < .001) and 2.15 (95% CI, 1.79-2.58) higher odds of receiving pharmacologic restraints ( P < .001) while in the ED. Conclusions and Relevance In this cross-sectional study of 1572 care encounters among 1119 patients, history of OOHP was associated with longer lengths of stay in the emergency department for children and adolescents who presented for mental health concerns. The findings highlight the need for further research on ways to mitigate the risk of extended emergency department stays for children with OOHP.
P-1228. Posaconazole Oral Suspension vs. Crushed Delayed-Release Tablets: Probability of Pharmacokinetic Target Attainment with Enteral Tube Administration
Bhattarai, Nirjan , O’Connell, Casey, Robinson, John, Cole, Kristin, Johnson, Tanner M , Stevens, Ryan W W, Wieruszewski, Patrick M. , Ilges, Dan , Stevens, Ryan W.

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1420 Get It

Abstract Background Posaconazole immediate release (IR) suspension is the standard product for enteral feeding tube (EFT) administration but has erratic pharmacokinetic behavior and results in sub satisfactory concentrations. Limited evidence suggests that the posaconazole oral delayed-release (DR) tablets may be crushed. Methods This was a retrospective cohort study of hospitalized adults who received EFT administration of posaconazole IR suspension or crushed DR tablets between 2018 and 2024. Patients were eligible if they had at least one serum concentration drawn ≥5 days after posaconazole initiation. The primary outcome was the attainment of therapeutic (≥700ng/mL for prophylaxis, ≥1,000ng/mL for treatment) serum concentration within 30 days. Secondary outcomes included time to therapeutic serum concentration, adverse drug effects, and frequency of clogged EFT. Multivariable cox proportional hazards regression was used to assess the relationship between posaconazole formulation and attainment of therapeutic concentrations while adjusting for confounding variables. Results Of the included patients, 100 received DR tablets and 48 received IR suspension. There were no significant differences in baseline characteristics or severity of illness. Among DR tablet and IR suspension recipients, 59% and 23% achieved therapeutic concentrations, respectively (p < 0.001). After adjusting for age, sex, BMI, drug interactions, posaconazole indication, malabsorptive gastrointestinal conditions, IR suspension was significantly less likely than crushed DR tablets to achieve therapeutic posaconazole concentrations within 30-days (HR 0.37, 95% CI 0.20-0.71; p < 0.003). The crushed DR tablet group required less total daily posaconazole to achieve therapeutic concentrations (400 vs 600 mg/day, p = 0.003). Clogged EFTs were more frequent in the crushed DR tablet group (27% vs 10%, p = 0.022), while no differences were observed in the occurrence of hepatotoxicity or hypokalemia. Conclusion Administration of crushed posaconazole DR tablets via EFT is more likely to attain therapeutic concentrations compared to IR suspension. The optimal technique for administering crushed DR tablets to prevent EFT complications warrants investigation. Disclosures Patrick M. Wieruszewski, PharmD, FCCM, Wolters Kluwer/UpToDate: Advisor/Consultant
Clinical associations of CSF TMEM106B in familial and sporadic frontotemporal lobar degeneration
Olzinski, Molly, Saloner, Rowan, Rajbanshi, Binita, Webb, Julia D, Li, Jingyao, Worringer, Katie, Heuer, Hilary W. , Ljubenkov, Peter A. , Staffaroni, Adam M. , Lago, Argentina Lario , Barragan, Eden V., Ramos, Eliana Marisa , Cook, Casey , Petrucelli, Leonard, Rademakers, Rosa, Boeve, Brad F, Rosen, Howard J., Boxer, Adam L., Cobigo, Yann , Saloner, Rowan , Loureiro, Joseph , VandeVrede, Lawren , Sanderson‐Cimino, Mark , Barragan, Eden V. , Petrucelli, Leonard , Rademakers, Rosa , Rosen, Howard J. , Rojas, Julio C., Boxer, Adam L.

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_103985 Get It

Abstract Background TMEM106B encodes a lysosomal protein and is a genetic susceptibility factor for frontotemporal lobar degeneration (FTLD). Aptamer‐based proteomics quantifies TMEM106B protein levels in CSF. The associations of CSF TMEM106B with measures of disease severity have not been previously evaluated, and the value of CSF TMEM106B as a clinical biomarker is unknown. Method CSF TMEM106B and NfL protein levels were quantified with aptamer‐based proteomics in participants from two independent cohorts: sporadic FTLD with neuropathology‐confirmed FTLD‐tau and FTLD‐TDP, clinically diagnosed PSP‐Richardson Syndrome, and controls (UCSF MAC, n = 95; mean age = 69 ± 6 yrs; 48% female) and familial FTLD comprised of presymptomatic and symptomatic FTLD mutation carriers with family non‐carrier controls (ALLFTD, n = 179; mean age = 49 ± 13 yrs; 53% female). The association between biomarkers and diverse measures of disease severity, including the CDR®+NACC‐FTLD and CDR®+NACC‐FTLD sum of boxes, were determined with linear regressions or mixed linear models. Associations with brain volumes were determined within the framework of voxel‐based morphometry. Result In both cohorts, at baseline, CSF TMEM106B did not differ by sex, age, FTLD phenotype, or CSF NfL. CSF TMEM106B was lower in cases with worse disease severity (Figure 1) and in participants with the protective TMEM106B rs1990622 G/G genotype, regardless of pathological diagnosis or FTLD‐causing mutation. Low CSF TMEM106B was associated with more severe longitudinal worsening in FTLD disease severity (Figure 2), basic and instrumental function, global cognition, executive function, and depression scores. These associations were weaker than those of NfL. Low CSF TMEM106B was associated with low brain volumes in frontal, parietal, and temporal regions (FWE‐corrected p < 0.05) (Figure 3A). CSF NfL negatively correlated (FWE‐corrected p < 0.05) with brain volumes in frontotemporal regions (Figure 3B). Conclusion CSF TMEM106B concentrations are influenced by the TMEM106B rs1990622 genotype, and correlate with disease severity and brain volume in both genetic and sporadic FTLD. Lower levels of CSF TMEM106B correlate with more severe disease and brain atrophy. Disease severity is more strongly associated with CSF NfL, while brain volumes are more strongly associated with CSF TMEM106B. CSF TMEM106B may have value as a biomarker of neurodegeneration in FTLD.
C9orf72 arginine‐rich dipeptide repeat proteins promote assembly and impair dynamics of processing body
Zhang, Yongjie, Wu, Yanwei, Noya, Jorge Alaiz, Jones, Caroline J., Jansen‐West, Karen , Daughrity, Lillian M. , Castanedes‐Casey, Monica , Petrucelli, Leonard, Shao, Wei , Gendron, Tania F. , Jones, Caroline J., Oskarsson, Björn , Dickson, Dennis W. , Petrucelli, Leonard

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S7 | Pages: No page available

10.1002/alz70861_108268 Get It

Abstract Background G 4 C 2 repeat expansions in C9orf72 gene are the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Mounting evidence indicates that dipeptide repeat (DPR) proteins translated from the expanded repeats, in particular poly(GR) and poly(PR), play a significant role. We and others have shown that these positively‐charged arginine‐rich DPR proteins induce the assembly of stress granules (SGs) and impair their disassembly. While distinct from SGs, processing bodies (PBs) are also cytoplasmic messenger ribonucleoprotein condensates that assemble upon stress. However, the impacts of arginine‐rich DPR proteins on PB assembly and dynamics have yet to be investigated. Method We conducted immunofluorescence staining for arginine‐rich DPR proteins, SG‐ and PB‐associated markers in cultured cells and mouse brain. Additionally, we performed in vitro liquid‐liquid phase separation (LLPS) using recombinant proteins and assessed molecular dynamics of SG and PB through fluorescence recovery (FRAP) after photobleaching in living cells. Result Here, we observed that both GFP‐(GR) 100 and GFP‐(PR) 100 formed cytosolic inclusions immunopositive PB proteins. Unlike GFP‐(GR) 100 and GFP‐(PR) 100 inclusions, cellular cytoplasmic GFP‐(GA) 100 inclusions did not contain PB proteins. We subsequently examined whether the phenomena observed in cultured cells occur in vivo. We observed that PB proteins were recruited to poly(GR) inclusions in cells with aggregated poly(GR). Next, we examined the dynamics of poly(GR)‐induced PBs in cultured cells using the FRAP technique. We observed that the recovery of stress‐induced PBs was more rapid than that of PBs in HEK293T cells expressing GFP‐(GR) 100 . Lastly, mechanistic studies revealed that poly(GR) interacts with PB proteins to form condensates in vitro via LLPS. Conclusion Our results provide both in vitro and in vivo evidence that arginine‐rich DPRs induce the spontaneous formation of PBs via LLPS. Our results also indicate that poly(GR)‐induced PBs are more stable than the transient and dynamic conventional PBs. Given that PBs uniquely enriched with mRNA degradation and decay factors, the consequences of impairing these processes are expected to contribute to abnormal RNA metabolism in c9FTD/ALS.
Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD
Su, Jingfen, Noya, Jorge Alaiz, Lingappa, Anuradha F. , Solas, Dennis, Tong, Jimei, Daughrity, Lillian M. , Castanedes‐Casey, Monica , Kurti, Aishe, Lingappa, Vishwanath R. , Petrucelli, Leonard , Zhang, Yong‐Jie , Alaiz Noya, Jorge, Daughrity, Lillian, Zhang, Yong-Jie , Dickson, Dennis W.

Mayo Clinic

Cells | December 17, 2025 | Volume: 14 | Issue: 24 | Pages: 2012

10.3390/cells14242012 | PMID 41440030 Get It

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal neurodegenerative diseases that share clinical and pathological features, as well as genetic causes. A G4C2 repeat expansion in chromosome 9 open reading frame 72 (C9orf72) is the most common genetic cause of ALS and FTD, collectively referred to as c9ALS/FTD. Assembly modulation is a new therapeutic approach which appears to target allosteric sites on aberrant forms of multi-protein complexes and restore them to the healthy state. Recent findings demonstrate that tetrahydroisoquinolone (THIQ)-based protein assembly modulators can ameliorate ALS/FTD-associated phenotypes in cellular and animal models. In the present study, we investigated the effects of PAV-615, a novel and advanced THIQ-based modulator, in a c9ALS/FTD mouse model expressing 149 G4C2 repeat expansions (referred to as 149R mouse model). Specifically, PAV-615 was administered to 5-month-old 149R mice via intraperitoneal injection for one month. Motor function was evaluated using the hang wire test, while anxiety-like behavior and hyperactivity were assessed using the open-field test. Pathological markers, including dipeptide repeat (DPR) proteins, phosphorylated TAR DNA-binding protein 43 (pTDP-43) and ataxin 2-positive stress granules, were quantified by Meso Scale Discovery and immunohistochemistry assays. Compared with vehicle-treated controls, PAV-615 significantly improved motor performance and modestly reduced anxiety-like behavior and hyperactivity in 149R mice. Moreover, PAV-615 treatment significantly decreased cortical DPR, pTDP-43 and ataxin 2-positive stress granule burdens. These results support assembly modulation as a promising therapeutic approach treatment of ALS/FTD.
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Gore, John L. , Wolff, Erika M. , Nash, Michael G. , Comstock, Bryan A. , Gilbert, Scott M. , Chang, Sam S., Chisolm, Stephanie , MacLean, Douglas B., Wright, Jonathan L. , Kates, Max , Pohar, Kamal S. , Guzzo, Thomas J., Bivalacqua, Trinity J, Nepple, Kenneth G. , Montgomery, Jeffrey S., Scarpato, Kristen R., Master, Viraj A. , Chen, David YT , Mossanen, Matthew , O’Neil, Brock , Tyson, Mark D. , Mansour, Ahmed M. , Chamie, Karim, Riggs, Stephen B. , Kukreja, Janet Baack , Peyton, Cheri L. , Nix, Jeffrey W. , Dickstein, Rian, Sankin, Alex , Lane, Brian R. , Bassett, Jeffrey C. , Patel, Sanjay , Lee, Eugene K. , Ritch, Chad R. , Follmer, Kristin , Kim, Sung Min , Kessler, Larry G. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J., Catto, James W.F. , Sankin, Alexander , Woldu, Solomon L , Master, Viraj A , Chen, David Y T , Daneshmand, Siamak , O'Neil, Brock B , Westerman, Mary E , Kamat, Ashish M. , Modi, Parth K , Peyton, Charles C , Gadzinski, Adam J , Shore, Neal , Patel, Sanjay , Ritch, Chad R , Follmer, Kristin M , Kim, Sung Min , Kessler, Larry G , Bivalacqua, Trinity J. , Daneshmand, Siamak , Westerman, Mary E. , Garg, Tullika K. , Shore, Neal D. , Morris, David S. , Macleod, Liam Connor , Lee, Jenney R. , Smith, Angela B. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J.

Mayo Clinic

Journal of Clinical Oncology | December 15, 2025 | Volume: 44 | Issue: 4 | Pages: 274-285

10.1200/jco-25-01324 | PMID 41397208 Get It

PURPOSE To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS This pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer–specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression. RESULTS Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health. Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%. CONCLUSION Most patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.